Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocolWilliam T. Creasman, David S. Miller, Shamshad Ali et al.|Gynecologic Oncology|2017Cited by 80
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and RecurrenceTheodore M. Brasky, Louise A. Brinton, Ashley S. Felix et al.|JNCI Journal of the National Cancer Institute|2016Cited by 57
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 StudyAshley S. Felix, Louise A. Brinton, Theodore M. Brasky et al.|International Journal of Cancer|2017Cited by 34
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP InhibitorsTomomi M. Yamamoto, Benjamin G. Bitler, Patricia Webb et al.|Molecular Cancer Therapeutics|2022Cited by 18
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 StudyAshley S. Felix, Louise A. Brinton, Richard G. Moore et al.|American Journal of Obstetrics and Gynecology|2018Cited by 16